Our runners up for Litigator of the Week include Goodwin Procter partners William Jay, Sarah Frederick, Brian Burgess and David Zimmer. They prevailed on summary judgment for pharmaceutical company Braeburn, which makes Brixadi, an injection used for the treatment of opioid use disorder. 

The U.S. Food & Drug Administration refused to give final approval to Brixadi because the agency previously granted a rival drug maker a three-year exclusivity period for a similar product. U.S. District Chief Judge Beryl Howell of the District of Columbia ordered the FDA on remand to reconsider its decision “with deliberate speed.”

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]